Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

PHASE3CompletedINTERVENTIONAL
Enrollment

542

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 6, 2018

Study Completion Date

July 6, 2018

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Afatinib

Patient will receive afatinib once daily

Trial Locations (33)

333

Chang-Gung Memorial Hospital, Linkou, Taoyuan

704

NCKUH, Tainan City

824

E-Da Hospital, Kaohsiung City

11490

Tri-Service General Hospital, Taipei

100071

307 Hospital of PLA, Beijing

100142

Beijing Cancer Hospital, Beijing

100853

Chinese PLA General Hospital, Beijing

110092

Max Super Speciality Hospital, Delhi, Delhi

169610

National Cancer Centre, Singapore

200030

Shanghai Chest Hospital, Shanghai

200032

Fudan University Shanghai Cancer Center, Shanghai

200433

Shanghai Pulmonary Hospital, Shanghai

210000

Jiangsu Cancer Hospital, Nanjing

276002

Lin Yi Tumor Hospital, Linyi

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

302004

SEAROC Cancer Centre, Jaipur

310022

Zhejiang Cancer Hospital, Hangzhou

400010

Prince Aly Khan Hospital, Mumbai

411001

Ruby Hall Clinic, Pune

422005

Shatabdi Superspeciality Hospital, Maharashtra

500004

Global Hospitals, Hyderabad

500034

Basavatarakam Indo - American Cancer Hospital & Research Ins, Hyderabad

510080

Guangdong Provincial People's Hospital, Guangzhou

560027

HCG Hospital, Bengaluru

560052

Vikram Hospital, Bangalore

600031

V S Hospital, Chennai

673002

P VS Hospital Pvt Ltd, Calicut

700053

B. P. Poddar Hospital & Medial Research Ltd, Kolkata,West Bengal

Unknown

Jilin Province Cancer Hospital, Changchun

Queen Mary Hospital, Hong Kong

Prince of Wales Hospital, Shatin

625 020

Asirvatham Multispeciality Hospital, Madurai

422 004

Curie Manavata Cancer Centre, Maharashtra

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY